Assignee
IMMUNOGEN INC
US·202 granted patents·128 pending applications·13,364 citations·filing 1992–2025
Top patents by PatentIndex Score
330 records- 0199US7851432B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Dec 14, 2010·54 cites·33 claims
- 0299US7601354B2Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2006·Granted Oct 13, 2009·161 cites·17 claims
- 0399US7368565B2Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2002·Granted May 6, 2008·239 cites·17 claims
- 0499US7303749B1Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2000·Granted Dec 4, 2007·226 cites·16 claims
- 0599US7276497B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2004·Granted Oct 2, 2007·402 cites·31 claims
- 0699US7276499B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2006·Granted Oct 2, 2007·58 cites·21 claims
- 0799US6716821B2Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the sameIMMUNOGEN INC·Filed 2001·Granted Apr 6, 2004·359 cites·92 claims
- 0899US6630579B2Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Oct 7, 2003·547 cites·16 claims
- 0999US6596757B1Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Jul 22, 2003·165 cites·48 claims
- 1099US6534660B1CC-1065 analog synthesisIMMUNOGEN INC·Filed 2002·Granted Mar 18, 2003·168 cites·9 claims
- 1199US6441163B1Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2001·Granted Aug 27, 2002·690 cites·27 claims
- 1299US6436931B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Aug 20, 2002·184 cites·24 claims
- 1399US6340701B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Jan 22, 2002·271 cites·24 claims
- 1499US6333410B1Process for the preparation and purification of thiol-containing maytansinoidsIMMUNOGEN INC·Filed 2000·Granted Dec 25, 2001·412 cites·34 claims
- 1599US5846545ATargeted delivery of cyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 8, 1998·531 cites·57 claims
- 1699US5585499ACyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 17, 1996·541 cites·8 claims
- 1799US5475092ACell binding agent conjugates of analogues and derivatives of CC-1065IMMUNOGEN INC·Filed 1994·Granted Dec 12, 1995·668 cites·8 claims
- 1898US9434748B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2015·Granted Sep 6, 2016·15 cites·25 claims
- 1998US7989598B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesIMMUNOGEN INC·Filed 2007·Granted Aug 2, 2011·46 cites·53 claims
- 2098US7557189B2Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2003·Granted Jul 7, 2009·109 cites·44 claims
- 2198US7473796B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Jan 6, 2009·55 cites·13 claims
- 2298US7388026B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2005·Granted Jun 17, 2008·68 cites·6 claims
- 2398US7342110B2Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2006·Granted Mar 11, 2008·82 cites·10 claims
- 2498US7301019B2Method for the preparation of maytansinoid estersIMMUNOGEN INC·Filed 2006·Granted Nov 27, 2007·41 cites·27 claims
- 2598US7097840B2Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesIMMUNOGEN INC·Filed 2001·Granted Aug 29, 2006·266 cites·44 claims
- 2698US6913748B2Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugsIMMUNOGEN INC·Filed 2003·Granted Jul 5, 2005·209 cites·34 claims
- 2798US6756397B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2002·Granted Jun 29, 2004·144 cites·5 claims
- 2898US6706708B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Mar 16, 2004·71 cites·12 claims
- 2998US6586618B1CC-1065 analog synthesisIMMUNOGEN INC·Filed 2002·Granted Jul 1, 2003·125 cites·2 claims
- 3098US5416064ACytotoxic agents comprising maytansinoids and their therapeutic useIMMUNOGEN INC·Filed 1992·Granted May 16, 1995·1.3k cites·20 claims
- 3198US5208020ACytotoxic agents comprising maytansinoids and their therapeutic useIMMUNOGEN INC·Filed 1992·Granted May 4, 1993·2.4k cites·18 claims
- 3297US10752683B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2019·Granted Aug 25, 2020·13 cites·31 claims
- 3397US9670279B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·26 cites·118 claims
- 3497US9359442B2Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2014·Granted Jun 7, 2016·29 cites·10 claims
- 3597US9169272B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2014·Granted Oct 27, 2015·19 cites·16 claims
- 3697US9133275B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2013·Granted Sep 15, 2015·45 cites·44 claims
- 3797US7655661B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2008·Granted Feb 2, 2010·35 cites·7 claims
- 3897US7655660B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2007·Granted Feb 2, 2010·39 cites·7 claims
- 3997US7411063B2Process for preparation of maytansinolIMMUNOGEN INC·Filed 2006·Granted Aug 12, 2008·31 cites·48 claims
- 4097US7049316B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2003·Granted May 23, 2006·77 cites·9 claims
- 4197US5639641AResurfacing of rodent antibodiesIMMUNOGEN INC·Filed 1992·Granted Jun 17, 1997·870 cites·16 claims
- 4296US10844135B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making saidIMMUNOGEN INC·Filed 2017·Granted Nov 24, 2020·7 cites·35 claims
- 4396US10208127B2Benzodiazepine derivativesIMMUNOGEN INC·Filed 2018·Granted Feb 19, 2019·6 cites·6 claims
- 4496US10179818B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2017·Granted Jan 15, 2019·6 cites·24 claims
- 4596US9868791B2Methods of preparation of conjugatesIMMUNOGEN INC·Filed 2016·Granted Jan 16, 2018·8 cites·12 claims
- 4696US9840564B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2016·Granted Dec 12, 2017·7 cites·3 claims
- 4796US9670280B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·19 cites·74 claims
- 4896US9670278B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·18 cites·104 claims
- 4996US9657100B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted May 23, 2017·16 cites·40 claims
- 5096US9598490B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Mar 21, 2017·18 cites·40 claims
Showing the top 50 of 330 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →